Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biomerica

0.6215
+0.04908.56%
Post-market: 0.64850.0270+4.34%19:58 EDT
Volume:198.71K
Turnover:121.73K
Market Cap:11.40M
PE:-1.87
High:0.6400
Open:0.5900
Low:0.5725
Close:0.5725
Loading ...

Biomerica Q2 Operating Expenses USD 1.43 Million

THOMSON REUTERS
·
15 Jan

Biomerica Q2 Net Income USD -950 Thousand

THOMSON REUTERS
·
15 Jan

Biomerica Q2 Gross Margin 27%

THOMSON REUTERS
·
15 Jan

Press Release: Biomerica Reports Second Quarter Fiscal 2025 Financial Results

Dow Jones
·
15 Jan

Sector Update: Health Care Stocks Climb Thursday Afternoon

MT Newswires Live
·
22 Nov 2024

Biomerica inFoods Technology Gets Three International Patents

MT Newswires Live
·
21 Nov 2024

BRIEF-Biomerica Secures Three Key International Patents For inFoods Technology To Address GERD, Crohn’s Disease, And Ulcerative Colitis

Reuters
·
21 Nov 2024

Biomerica Inc: Patents Secured Apply to Countries Under European Patent Organization

THOMSON REUTERS
·
21 Nov 2024

Biomerica Secures Three Key International Patents for Infoods® Technology to Address Gerd, Crohn’s Disease, and Ulcerative Colitis

THOMSON REUTERS
·
21 Nov 2024

Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis

GlobeNewswire
·
21 Nov 2024

BRIEF-Nasdaq Grants Biomerica An Additional 180 Days To Meet Listing Compliance Requirements

Reuters
·
07 Nov 2024

Biomerica granted additional 180-day period to meet listing compliance

TIPRANKS
·
07 Nov 2024

Nasdaq Grants Biomerica an Additional 180 Days to Meet Listing Compliance Requirements

THOMSON REUTERS
·
07 Nov 2024

Biomerica Inc - Extension Allows Biomerica Until May 5, 2025 to Regain Compliance

THOMSON REUTERS
·
07 Nov 2024

Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements

GlobeNewswire
·
07 Nov 2024

Biomerica announces direct-to-consumer availability of inFoods IBS test

TIPRANKS
·
30 Oct 2024